Liver cancer study tracks Real-World treatments and survival
NCT ID NCT07449637
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study watches 200 adults with intermediate-stage liver cancer to see which treatments doctors actually use and how long patients survive. It does not test a new drug or procedure. The goal is to learn from real-world care to help guide future treatment decisions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 200 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Mar 2026
An estimate. Start dates often move.
- Expected to finish
-
Jul 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with intermediate-stage hepatocellular carcinoma (BCLC-B) treated at Sohag Oncology Center.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Aged ≥18 years. * Both sexes. * Diagnosis of hepatocellular carcinoma based on accepted radiologic or histologic criteria. * Classified as intermediate stage (BCLC-B) at time of decision for first-line treatment. * Child-Pugh A or B. * ECOG performance status 0-1. Exclusion Criteria: * BCLC A, C, or D at diagnosis. * Prior curative therapy (resection, transplantation, curative ablation). * Missing essential data (imaging, liver function, treatment records). * Mixed HCC-cholangiocarcinoma.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BCLC stage B hepatocellular carcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Sohag Oncology Center
Sohag, Sohag Governorate, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Radioactive beads offer new hope for inoperable liver cancer
- AI scans 3000 liver cancer patients to pick best therapy
- Immunotherapy duo after radiation shows promise for untreatable liver cancer
- Liver cancer drug combo shows promise but study halted early
- New drug combo shows promise for Tough-to-Treat liver cancer